Results 121 to 130 of about 3,235 (226)

Effectiveness of tezepelumab in preventing relapse of eosinophilic granulomatosis with polyangiitis: A case report.

Respiratory Investigation
A 54-year-old woman diagnosed with eosinophilic granulomatosis accompanied by polyangiitis (EGPA) was in remission with prednisolone (PSL) and mepolizumab treatment. During the disease course, vasculitis recurrence was not apparent, but her asthma became
Nanase Watatani, Yoshiyuki Kawabata, Kunita Yuuki, K. Yoshikawa, Akiko Sano, Yuji Tohda, H. Matsumoto   +6 more
semanticscholar   +1 more source

Tezepelumab: patient selection and place in therapy in severe asthma

Journal of International Medical Research
Asthma is a disease characterised by heterogeneous and multifaceted airway inflammation. Despite the availability of effective treatments, a substantial percentage of patients with the type 2 (T2)-high, but mainly the T2-low, phenotype complain of persistent symptoms, airflow limitation, and poor response to treatments.
Francesco Menzella, Sara Munari, Lorenzo Corsi, Silvia Tonin, Walter Cestaro, Andrea Ballarin, Ariel Floriani, Cristina Dartora, Gianenrico Senna   +8 more
openaire   +3 more sources

Three Biologic-Naïve Patients with Allergic Bronchopulmonary Aspergillosis Showing Significant Clinical Improvement with Tezepelumab

Journal of Asthma and Allergy
Allergic bronchopulmonary aspergillosis is characterized by hypersensitivity to Aspergillus spp. and often causes intractable asthma. Studies have been conducted on biologics administered to patients with allergic bronchopulmonary aspergillosis; however,
Masafumi Yamaguchi, A. Yamazaki, Hiroaki Nakagawa, D. Kinose, Yasutaka Nakano   +4 more
semanticscholar   +1 more source

Spanish translation: Tezepelumab for the treatment of severe asthma: a plain language summary of the PATHWAY and NAVIGATOR studies

What is this summary about? This is a summary of the results of 2 clinical studies that looked at a medicine called tezepelumab. Tezepelumab is approved in the United States of America (USA), the European Union (EU) and several other countries for the ...
Gun Almqvist (3626828), Christopher E Brightling (7668680), Johan Bimmel (18085726), Janet M Griffiths (17065597), Arnaud Bourdin (376853), Elliot Israel (153177), Andrew Menzies-Gow (603619), Karin Bowen (6991781), Michael E Wechsler (13266985), Jonathan Corren (9654556), Gene Colice (5129612), Anthony McGuinness (18085729), Sandhia Ponnarambil (14640482)   +12 more
core   +1 more source

Tezepelumab (Tezspire®) : new biological treatment of severe asthma.

editorial reviewedHere we present pharmacological and clinical properties of a new biological targeting TSLP (Thymic Stromal LymphoPoietin). Tezspire® is the name of this targeted treatment which contains 210 mg tezepelumab administered subcutaneously ...
Moermans, Catherine, Schleich, FLorence, SABBE, Mare, Louis, Renaud   +3 more
core  

Persistent presumed allergic fungal rhinosinusitis during tezepelumab therapy with improvement after revision surgery: a case report. [PDF]

Front Allergy
Alsultan BSH, Alshehri AG, Sarhan LA, Alsultan GSH, Shabi Y.   +4 more
europepmc   +1 more source

German translation: Tezepelumab for the treatment of severe asthma: a plain language summary of the PATHWAY and NAVIGATOR studies

What is this summary about? This is a summary of the results of 2 clinical studies that looked at a medicine called tezepelumab. Tezepelumab is approved in the United States of America (USA), the European Union (EU) and several other countries for the ...
Gun Almqvist (3626828), Christopher E Brightling (7668680), Johan Bimmel (18085726), Janet M Griffiths (17065597), Arnaud Bourdin (376853), Elliot Israel (153177), Andrew Menzies-Gow (603619), Karin Bowen (6991781), Michael E Wechsler (13266985), Jonathan Corren (9654556), Gene Colice (5129612), Anthony McGuinness (18085729), Sandhia Ponnarambil (14640482)   +12 more
core   +1 more source

Improvement of Severe Volume Dependent Airway Closure With Tezepelumab: A Case Report. [PDF]

Clin Case Rep
Suter P, Greig R, Chan R, Lipworth BJ.
europepmc   +1 more source

Tezepelumab in real-world US patients with severe asthma across phenotypes and underrepresented populations: the phase 4 PASSAGE study. [PDF]

Am J Respir Crit Care Med
Lugogo NL, Akuthota P, Sumino K, Burnette AF, Mathur SK, Lindsley AW, Llanos JP, Marchese C, Ambrose CS, Emmanuel B.   +9 more
europepmc   +1 more source

Real world effects of tezepelumab on small airways dysfunction in severe refectory asthma.

Annals of Allergy, Asthma & Immunology
Robert Greig, R. Chan, Tom Fardon, B. Lipworth   +3 more
semanticscholar   +1 more source